Elevated MBL Concentrations Are Not an Indication of Association Between the MBL2 Gene and Type 1 Diabetes or Diabetic Nephropathy

Mari A. Kaunisto,1,2 Lisa Sjölind,1,3 Riitta Sallinen,1 Kim Pettersson-Fernholm,1,3 Markku Saraheimo,1,3 Sara Fröjdö,1,3 Carol Forsblom,1,3 Johan Fagerudd,1,3 Troels K. Hansen,4 Allan Flyvbjerg,4 Maija Wessman,1,2 and Per-Henrik Groop,1,3 for the FinnDiane Study Group*

OBJECTIVE—Mannose-binding lectin (MBL) is an essential component of the acute-phase immune response and may thus play a role in the pathogenesis of type 1 diabetes and diabetic nephropathy. The serum concentration of MBL is mainly genetically determined, and elevated concentrations have been associated with both type 1 diabetes and diabetic nephropathy. Previous genetic studies have not been conclusive due to the small number of patients and polymorphisms studied. We investigated whether MBL2 polymorphisms are associated with type 1 diabetes or diabetic nephropathy and whether patients with nephropathy have elevated MBL concentrations as indicated previously. Furthermore, we studied the association between MBL2 polymorphisms and MBL concentration.

RESEARCH DESIGN AND METHODS—We genotyped 20 MBL2 single nucleotide polymorphisms (SNPs) in a large, well-characterized Finnish case-control sample consisting of 1,297 patients with type 1 diabetes with or without nephropathy and 701 nondiabetic individuals. The serum concentration of MBL was available for 1,064 patients.

RESULTS—We found that 19 SNPs were associated with the MBL concentration (P = 3 × 10⁻¹⁸⁻⁷ × 10⁻³⁴). MBL concentrations were higher in patients with macroalbuminuria compared with patients without nephropathy even when the patients were stratified by the MBL2 genotypic background in accordance with previous studies. However, no evidence of association between any of the SNPs or their haplotype combinations and type 1 diabetes or diabetic nephropathy was observed.

CONCLUSIONS—Although most of the MBL2 SNPs studied were associated with the MBL concentration, no common variations (neither single SNPs nor their haplotype combinations) confer risk of type 1 diabetes or diabetic nephropathy. Diabetes 57:1710–1714, 2009

D iabetic nephropathy is a common and devastating long-term complication of diabetes, but its pathogenesis is poorly understood. Low-grade inflammation and complement activation may, however, play a role in the pathogenesis of both type 1 diabetes and its complications (1–3). Mannose-binding lectin (MBL) is a C-type lectin secreted by the liver as a component of the acute-phase immune response, and its binding to carbohydrate structures on microorganisms activates the MBL complement pathway (4,5).

Serum concentrations of MBL are significantly elevated in patients with type 1 diabetes (1,2) and even more elevated in those patients with micro- and macrovascular complications (6,7). Moreover, high MBL concentrations early in the course of type 1 diabetes predict later development of micro- or macroalbuminuria (8), and MBL deficiency attenuates renal changes in mice with experimentally induced diabetes (9).

The MBL2 gene (OMIM# +154545) on chromosome 10q21 consists of five exons, four of which are protein coding (10,11). The serum concentration of MBL is largely genetically determined (estimated heritability 0.96), and substantial interindividual variation exists (12). Three non-synonymous variants in exon 1 named alleles B (G54D/rs1800450), C (G57E/rs1800451), and D (R52C/rs5003737) decrease MBL concentration considerably due to incorrect assembly of the mature MBL protein (13). Furthermore, several single nucleotide polymorphisms (SNPs), especially promoter variants H/L (rs11003125), P/Q (rs7095891), and X/Y (rs7096206), modify the MBL concentration (13). Based on linkage disequilibrium (LD) between these six promoter and exon 1 variants, seven common MBL2 haplotypes can be identified (13).

The low-expression MBL2 variant carriers have an increased infection risk in situations of impaired immunity (14), and the role of MBL2 in various autoimmune diseases has been actively studied (15,16). Previous studies on the relationship between MBL2 and type 1 diabetes show contradictory results (1,6,17–19). This may be due to the fact that only a few polymorphisms were studied in relatively small samples, except in the Finnish study of 470 patients (17). Only the Danish study had nephropathy status available and reported association between the high-expression MBL2 genotypes and diabetic nephropathy (6). Thus, the question whether genetic variation in the MBL2 gene confers susceptibility to type 1 diabetes or diabetic nephropathy is still warranted.
Genetic Power Calculator (http://pngu.mgh.harvard.edu/mean age 43.9 years). The power of our study sample was calculated using the database release 21a (CEU) (http://www.hapmap.org/) and the Haploview SNP selection and genotyping.

University Central Hospital. Informed written consent was obtained from all Study protocol was approved by the ethics committee of the Helsinki population with pairwise

Cockcroft-Gault formula adjusted for body surface area (ref. 20). *creatinine values were derived from the last central laboratory measurements. Therefore, single values may exceed or fall behind the (on the AER in at least two of three consecutive overnight or 24-h urine collections. A fourth patient group consisted of patients on dialysis

DIABETES, VOL. 57, JULY 2009 1711

HapMap SNPs having a minor allele frequency (MAF) [46.1 years] from all over the country were applied and compared with an age-

MBL was determined in 1,064 patients (available in the supplemental methods required to have a duration of diabetes over 15 years. Serum concentration of treatment within 1 year of diagnosis. Patients were classified into four groups on the onset of diabetes before 35 years of age and initiation of permanent insulin
diabetic nephropathy.

Here, we studied whether the MBL2 gene polymorphisms are associated with type 1 diabetes or diabetic nephropathy by genotyping a dense set of SNPs in a large well-characterized Finnish case-control sample and evaluated the association between MBL concentration and diabetic nephropathy.

RESEARCH DESIGN AND METHODS

We studied 1,297 patients with type 1 diabetes from the nationwide Finnish Diabetic Nephropathy Study (FinnDiane). Patients were required to have an onset of diabetes before 35 years of age and initiation of permanent insulin treatment within 1 year of diagnosis. Patients were classified into four groups based on the urinary albumin excretion rate (AER) or the presence of end-stage renal disease (ESRD) (Table 1). Patients with normal AER were required to have a duration of diabetes over 15 years. Serum concentration of MBL was determined in 1,064 patients (available in the supplemental methods at http://diabetes.diabetesjournals.org/cgi/content/full/db08-1495/DC1). For nondiabetic control subjects, 701 Finnish blood donors (40% men; mean age 46.1 years) from all over the country were applied and compared with an age- and sex-matched subgroup of patients with type 1 diabetes (n = 701; 40% men; mean age 43.9 years). The power of our study sample was calculated using the Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/plink/) (21). Study protocol was approved by the ethics committee of the Helsinki University Central Hospital. Informed consent was obtained from all patients.

SNP selection and genotyping. We selected 17 SNPs using the HapMap database release 21a (CEU) (http://www.hapmap.org/) and the Haplov Tagger program (http://www.broad.mit.edu/mpg/haplov/index.php) (22) from a 23-kb region covering the 6.3-kb MBL2 gene and the 5′ untranslated region and 3′ untranslated region. SNPs were chosen to capture all known HapMap SNPs having a minor allele frequency (MAF) >0.01 in the CEU population with pairwise r² ≥ 0.8. Additionally, three functional SNPs (allele C, allele D, and variant H/L) were genotyped (supplementary Table 1). For genotyping, see the supplemental methods in the online appendix.

Statistical analyses of MBL concentrations. Comparisons between groups were performed using the Mann-Whitney U test because MBL concentrations were not normally distributed. These analyses were done using the SPSS v. 15.0 software (SPSS, Chicago, IL).

Association analyses. Allele frequencies and genotype distributions for single SNPs were compared between the control subjects and the matched subset of patients with type 1 diabetes as well as between patients with macroalbuminuria and patients with type 1 diabetes but normal AER. We also

compared patients with ESRD with patients with normal AER and compared a combined group of patients with macroalbuminuria or ESRD with patients with normal AER. An allelic association χ² test and three genotypic tests (general, dominant, and recessive models) were performed for each SNP. Association of the SNPs with MBL concentration was studied using the asymptotic Wald test. Additionally, analyses with adjustment for potential confounders (age, sex, A1C, diabetes duration, and history of smoking) were performed. The PLINK analysis program, version 1.00, was applied in all analyses (http://pngu.mgh.harvard.edu/~purcell/plink/) (23). For haplotype association analyses, see the supplemental methods in the online appendix.

RESULTS

SNP genotyping. The 17 tag SNPs genotyped captured the 68 HapMap SNPs having an MAF>0.01 with a mean pairwise r² of 0.97. The average distance between all of the 20 studied SNPs is 1.2 kb. All SNPs were in Hardy-Weinberg equilibrium (P > 0.01) both in the healthy control subjects (supplementary Table 1) and in type 1 diabetic patients (data not shown). Pairwise LD values (r²) between the SNPs are shown in supplementary Fig. 1. The frequencies of the exon 1 variants were 0.13 (B), 0.06 (C), and 0.006 (D) in the healthy subjects, which is in line with the previously published frequencies in the Finnish population (17). Of the patients with diabetes, 30.6% were heterozygous carriers of one of these variants (A/O genotype) and 5.8% were homozygotes or compound heterozygotes (O/O genotype).

MBL concentrations. The median serum concentration of MBL was higher in patients with macroalbuminuria (1,881 µg/l [interquartile range 608–3,124]) than in patients with normal AER (1,548 µg/l [514–2,635]); P = 0.019 (Fig. 1). Supplementary Table 2 shows the distribution of the MBL2 diplotype and the corresponding median MBL concentrations. As expected, the carriers of the exon 1 variants and the individuals homozygous for the X promoter polymorphism had clearly reduced MBL concentrations, with a median of 397 µg/l. When the patients were stratified both by nephropathy status and MBL2 diplotype

| AER Criteria | Normal AER | Microalbuminuria | Macroalbuminuria | ESRD | P      |
|--------------|------------|------------------|------------------|------|--------|
| n            | 477        | 276              | 366              | 178  | <0.0001|
| Male/female  | 40/60      | 59/41            | 59/41            | 58/42| <0.0001|
| Age (years)  | 42.5 ± 10.1| 37.3 ± 10.9*     | 39.0 ± 9.0*      | 42.2 ± 7.5*‡|| <0.0001|
| Duration of diabetes (years) | 28.5 ± 7.1 | 25.0 ± 9.4*      | 27.2 ± 6.4$§     | 30.1 ± 6.5|| <0.0001|
| Time to DNP (years) | NA         | 18.3 ± 6.3       | 17.1 ± 5.1       | 0.039|
| BMI (kg/m²)  | 24.8 ± 2.9 | 25.7 ± 3.5†     | 25.7 ± 3.8†      | 23.9 ± 3.5†|| <0.0001|
| SBP (mmHg)   | 132 ± 16   | 136 ± 17         | 144 ± 19$‡      | 154 ± 22$‡|| <0.0001|
| DBP (mmHg)   | 78 ± 9     | 81 ± 10*§        | 84 ± 10*§        | 88 ± 11$‡|| <0.0001|
| Retinal laser treatment | 29         | 48*              | 61*‡            | 98*$|| <0.0001|
| Hypertension | 51         | 86*              | 98*$‡           | 97*$|| <0.0001|
| Antihypertensive treatment | 18         | 66*              | 97*‡             | 92*‡|| <0.0001|
| A1C (%)      | 8.1 ± 1.2  | 8.8 ± 1.4*       | 9.0 ± 1.6*‡      | 8.7 ± 1.5*‡|| <0.0001|
| AER (mg/24 h) | 7 (1–85)* | 59 (2–613)*§   | 587 (4–8345)*‡$§ | —   | <0.0001|
| eGFR (ml/min per 1.73 m²) | 80.8 ± 18.1 | 95.7 ± 25.3*‡ | 64.6 ± 31.8*§    | —   | <0.0001|
| Serum creatinine (µmol/l) | 84 (43–144) | 88 (35–194)‡ | 127 (20–1,278)*‡ | —   | <0.0001|

Data are means ± SD, median (interquartile range), or percent unless otherwise indicated. Patients were classified into three groups based on the AER in at least two of three consecutive overnight or 24-h urine collections. A fourth patient group consisted of patients on dialysis (n = 34) and patients who had received a kidney transplant (n = 144) and were thus classified as having ESRD. The 24-h AER and serum creatinine values were derived from the last central laboratory measurements. Therefore, single values may exceed or fall behind the thresholds for the classification due to effects of treatment. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault formula adjusted for body surface area (ref. 20). *P < 0.0001 versus normal AER. †P < 0.01 versus normal AER. $P < 0.01 versus microalbuminuria. ¥P < 0.01 versus macroalbuminuria. ²P < 0.01 versus macroalbuminuria. DBP, diastolic blood pressure; DNP, diabetic nephropathy; SBP, systolic blood pressure.
Association analyses between single SNP and type 1 diabetes. There were no significant differences in allele frequencies or genotype distributions between the patients with type 1 diabetes and nondiabetic control subjects (supplementary Table 3). Although nominal evidence of allelic association (P = 0.01–0.04) was seen for four SNPs (rs930507, rs2384045, rs11003132, and rs11003137), the P values did not remain significant after correction for the number of tests performed. Men and women were also tested separately, but no significant P values were achieved (data not shown).

Association analyses between single SNPs and nephropathy. Association analyses showed no significant differences in allele frequencies or genotype distributions between patients with macroalbuminuria and patients with type 1 diabetes but normal AER (supplementary Table 4). When patients with ESRD were compared with patients with normal AER, significant evidence of association was observed for rs920727. The MAF of this SNP was 0.19 in patients with normal AER and 0.29 in patients with ESRD (P = 0.00009). The genotype distribution of this SNP was also significantly different between these groups (P = 0.0002), with homozygous individuals being more common among ESRD patients (10 vs. 3%). The same SNP had a P value of 0.006 in the genotypic test when a combined group of patients with macroalbuminuria or ESRD was compared with patients with normal AER. No other SNP provided evidence of association in these analyses. The analyses were also performed with adjustment for potential confounders (supplementary Table 4). None of the SNPs showed evidence of association with nephropathy after the adjustment procedure.

Association analyses between single SNPs and MBL concentrations. All SNPs, except rs10824793, were associated with MBL concentration (supplementary Table 5). The SNPs showing the strongest associations were rs7899547 (P = 3.0 × 10−81), rs1031101 (tagging the B allele; P = 8.0 × 10−76), rs2384045 (P = 2.2 × 10−59), and rs920727 (P = 7.6 × 10−45). The promoter variants H/L (rs11003125) and P/Q (tagged by rs920724) had P values of 8.8 × 10−25 and 6.1 × 10−16, respectively, whereas the alleles C and D had P values of 1.5 × 10−7 and 9.0 × 10−10, respectively. The analyses were also performed with adjustment for potential confounders (supplementary Table 5).

Haplotype and diplotype analyses. The haplotypes constructed using the Haplovie program were studied for association with type 1 diabetes and diabetic nephropathy. The results did not improve compared with the single SNP results. The distribution of the MBL2 diplotype, diplotype categories, and the high- and low-MBL genotypes in each patient group is presented in Table 2. There were no differences in the frequency of the high-MBL genotypes between the patients with normal AER (0.60) and macroalbuminuria (0.61; P = 0.39). Similarly, when the distribution of the six diplotype categories was analyzed, no differences were seen (P = 0.63).

DISCUSSION

Our study showed no evidence of association between the MBL2 SNPs and type 1 diabetes, although weak association signals (uncorrected P = 0.01–0.04) were seen for four SNPs. This is in accordance with most of the previous studies (1,6,17,18). Importantly, using tag SNPs, we have
captured information on the whole gene and its surroundings, whereas the other studies addressed only the functional exon 1 variants.

In a Danish study (6), genotypes producing high MBL concentrations were more common in patients having diabetic nephropathy than in patients with normal AER. We found no evidence of such an association, although our study sample was about double the size (6). Furthermore, we thoroughly studied association between both single MBL2 SNPs and haplotypes and nephropathy, but all the results were negative.

In accordance with previous studies (6,7), we showed that the median serum MBL concentration was significantly higher in patients with macroalbuminuria compared with the patients with normal AER. This result persisted even when the patients were stratified by the MBL diplotype categories, although the difference was significant in only two of them. Thus, it seems that the high serum MBL concentration in patients with nephropathy is likely to reflect some still unknown pathogenic event such as chronic low-grade inflammation. Further studies are needed to resolve whether elevated MBL concentrations are a marker associated with some other contributing factor or a consequence of nephropathy or diabetic microvascular complications in general.

The minor allele of the SNP rs920727 was more common in ESRD patients than in the other patients (0.29 vs. 0.19–0.20). Furthermore, the frequency of the high-MBL genotypes was somewhat lower in the ESRD patients than in the other groups (0.54 vs. 0.60–0.61), potentially explaining the relatively low MBL concentration in the ESRD patients. However, we do not consider these differences as an indication of a causal association with ESRD phenotype. Most likely they are due to chance or even signs of selective mortality. Supporting this hypothesis, evidence exists that mortality of patients with type 2 diabetes is higher among individuals with an MBL concentration ≥1,000 μg/l (24). Moreover, most of the ESRD patients in our study have received a kidney transplant, and graft

### TABLE 2

| MBL2 diplotype | Normal AER | Microalbuminuria | Macroalbuminuria | ESRD |
|----------------|------------|------------------|------------------|------|
| Low-MBL genotypes |           |                  |                  |      |
| YA/YA          | HYP/YHPA  | 63               | 37               | 58   | 19  |
| HYP/LYQA       | 70         | 28               | 13              | 46   | 16  |
| HYP/LYPA       | 16         | 13               | 12              | 8    | 13  |
| LYQA/LYQA      | 19         | 8                | 13              | 8    | 5   |
| LYPA/LYQA      | 8          | 6                | 7               | 2    | 5   |
| LYPA/LYP       | 2          | 2                | 0               | 1    |     |
| Total          | 178 (37.6) | 94 (34.2)        | 136 (37.3)      | 59 (33.9) |
| YA/XA          | HYP/LXP   | 70               | 41               | 54   | 24  |
| LYQA/LXP       | 29         | 23               | 27              | 9    |     |
| LYP/LXP        | 7          | 10               | 6               | 2    |     |
| Total          | 106 (22.4) | 74 (26.9)        | 87 (23.8)       | 35 (20.1) |
| Total          | 284 (59.9) | 168 (61.1)       | 223 (59.1)      | 94 (54.0) |
| High-MBL genotypes |      |                  |                  |      |
| YA/XA          | LXPA/LXP  | 27 (5.7)         | 12 (4.4)        | 12 (3.3) | 8 (4.6) |
| YA/YO          | HYP/LYP   | 46               | 24               | 27   | 19  |
| LYQA/LYP       | 20         | 11               | 18              | 7    |     |
| LYPA/LYP       | 3          | 4                | 2               | 4    |     |
| LYPA/LYQC      | 3          | 3                | 1               | 1    |     |
| LYPA/LYPQ      | 1          | 1                | 1               | 1    |     |
| HYP/HYPD       | 21         | 10               | 18              | 8    |     |
| LYQA/HYPD      | 9          | 8                | 13              | 4    |     |
| LYP/LYPD       | 3          | 2                | 2               | 0    |     |
| Total          | 109 (23.0) | 64 (23.3)        | 83 (22.7)       | 44 (25.3) |
| XA/YO          | LXPA/LYP  | 24               | 6                | 18   | 8   |
| LXPA/LYQC      | 2          | 0                | 1               | 2    |     |
| LYP/HYPD       | 8          | 9                | 8               | 3    |     |
| Total          | 34 (7.2)  | 15 (5.5)         | 27 (7.4)        | 13 (7.5) |
| YO/YO          | LYP/LYP   | 8                | 4                | 9    | 6   |
| LYP/LYQC       | 1          | 0                | 0               | 3    |     |
| LYP/HYPD       | 9          | 8                | 5               | 2    |     |
| HYPD/HYPD      | 2          | 4                | 1               | 4    |     |
| LYQC/HYPD      | 3          | 2                | 2               | 0    |     |
| Total          | 20 (4.2)  | 16 (5.8)         | 20 (5.5)        | 15 (8.6) |
| All            | 474 (100) | 275 (100)        | 365 (100)       | 174 (100) |

Data are n or n (percent). The MBL2 haplotypes were determined based on the co-occurrence of the three promoter variants (H/L, rs11003125; X/Y, rs7096206; and P/Q, rs7095894) and the three exon 1 variants (B, rs1800450; C, rs1800451; and D, rs5030737). Diplotypes were grouped into six categories (YA/YA, YA/XA, XA/XA, YA/YO, XA/YO, and YO/YO) based on the X/Y polymorphism and the presence of any of the exon 1 variants (B, C, and D), collectively designated with O, and further into low- and high-MBL genotypes. There were no differences in the frequency of the high-MBL genotypes between the patients with normal AER and macroalbuminuria. However, the frequency of the high-MBL genotypes within the group of ESRD patients (0.54) was lower than in patients with normal AER (0.60), although this difference was not significant \( P = 0.10 \).
rejection is less common for the group of patients with low MBL concentrations (25).

Many of the SNPs showing strong association with MBL concentration (including the ESRD-associated rs9207277) did not belong to the group of SNPs forming the common MBL2 haplotypes. Some of these variants may have an independent effect on the MBL concentration or tag other still unknown functional variants. However, this somewhat surprising association pattern can mainly be explained by LD between the associated and haplotype-forming SNPs (supplementary Table 6).

Our study sample has a reasonably high power to detect associations with relatively common SNPs (population frequency >20%) with modest effects. The previously described higher median MBL concentration in patients with macroalbuminuria (6,7) was evident also in our sample. We have thoroughly covered the common variation within the MBL2 gene in carefully characterized Finnish type 1 diabetic patients. We conclude that although most of the MBL2 SNPs studied were associated with the MBL concentration, neither any single SNP nor any of their haplotype combinations confer risk of type 1 diabetes or diabetic nephropathy.

ACKNOWLEDGMENTS

This study was supported by grants from the Academy of Finland (124280 and 214335 to M.W.), the Victoria Foundation (to L.S.), the Waldemar von Frenckell Foundation (to L.S.), the Sigrid Juselius Foundation, the Folkhalsan Research Foundation, the Wilhelm and Else Stockmann Foundation, the Diabetes Research Foundation (to M.W.), the Research Funds of the Helsinki University Central Hospital, Medicinska Understödsföreningen Liv och Hälsa r.f., and the Danish Medical Research Council (to T.K.H. and A.F.).

No potential conflicts of interest relevant to this article were reported.

Parts of this work were presented at the 19th annual meeting of the European Diabetic Nephropathy Study Group, Helsinki, Finland, 19 May 2008.

We thank all the patients participating in the FinnishDiabe Study. We acknowledge the assistance of the Finnish Diabetic Nephropathy Study Group and, especially, the skilled technical assistance of Maija Parkkonen, Karen Mathiassen, Dorte Wulff, Sinikka Lindh, and Anna Sandelin. The valuable comments of Jaakko Kaukonen are gratefully acknowledged. SNP genotyping using the Sequenom technology was performed by the Finnish Genome Center.

REFERENCES

1. Bouwman LH, Eerlegh P, Terpstra OT, Daha MR, de Knijff P, Ballieux BE, Bruining GJ, van der Silk AR, Roos A, Roep BO. Elevated levels of mannan-binding lectin at clinical manifestation of type 1 diabetes in juveniles. Diabetes 2005;54:3002–3006
2. Hansen TK, Thiel S, Knudsen ST, Grahnolt CH, Christiansen JS, Mogensen CE, Poulsen PL. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 2003;88:4857–4861
3. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003;46:1402–1407
4. Thiel S, Vorup-Jensen T, Stover CM, Schweable W, Laursen SB, Poulsen K, Willis AE, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997;386:506–510
5. Turner MW, Hannas RM. Mannose-binding lectin: structure, function and disease associations. Rev Immunogenet 2008;2:295–322
6. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A. Association between mannan-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004;53:1570–1576
7. Sarathadhe M, Forshblom C, Hansen TK, Teppo AM, Fagerudd J, Pettersson-Fernholm K, Thiel S, Tarnow L, Ebeling P, Flyvbjerg A, Groop PH. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 2005;48:108–202
8. Holvind P, Hansen TK, Tarnow L, Thiel S, Steffensen R, Flyvbjerg A, Parving HH. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 2005;54:1522–1527
9. Ostergaard J, Thiel S, Gadjeva M, Hansen TK, Rasch R, Flyvbjerg A. Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. Diabetologia 2007;50:1541–1549
10. Naito H, Ikeda A, Hasegawa K, Oka S, Uemura K, Nakai N, Kawai T. Characterization of human serum mannan-binding protein promoter. J Biochem 1999;126:1004–1012
11. Sastry K, Herman GA, Day L, Deignan E, Bruns G, Morton CC, Ezekowitz RA. The human mannose-binding protein gene: exonic structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989;170:1175–1189
12. Husby S, Herskind AM, Knip M, Simell O, Ilonen J, Vaarala O. Heritability estimates for the constitutional levels of the collectins mannan-binding lectin and lung surfactant protein D: a study of unselected like-sexed mono- and dizygotic twins at the age of 6–9 years. Immunology 2002;106:389–394
13. Garred P, Larsen S, Foy R, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun 2006;7:85–94
14. Garred P, Madsen HO, Hofmann B, Sveigaard A. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 1995;346:941–943
15. Maury CP, Aittoniemi J, Tiittinen S, Laiko K, Kaarella H, Hurme M. Variant mannan-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J Intern Med 2007;262:466–469
16. Monticello OA, Mucenic T, Xavier RM, Brenol JC, Chies JA. The role of mannan-binding lectin in systemic lupus erythematosus. Clin Rheumatol 2008;27:413–419
17. Aittoniemi J, Turpeinen H, Tiittinen M, Knip M, Simell O, Ilonen J, Vaarala O. Relation among mannan-binding lectin 2 genotype, beta-cell autoantibodies, and risk for type 1 diabetes in finnish children. Hum Immunol 2008;69:108–111
18. Tsutsumi A, Ikegami H, Takahashi R, Murata H, Goto D, Matsumoto I, Fujisawa T, Sumida T. Mannose binding lectin gene polymorphism in patients with type i diabetes. Hum Immunol 2003;64:621–624
19. Aranjo J, Brandao LA, Guinarares RL, Santos S, Falcao EA, Milanese M, Segat L, Souza PR, de Lima-Filho JL, Crovella S. Mannose binding lectin gene polymorphisms are associated with type 1 diabetes in brazilian children and adolescents. Hum Immunol 2007;68:739–743
20. Cockcroft DW, Gauld MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
21. Poccelli S, Chen SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19:149–150
22. Barrett JC, Fry B, Maller J, Daly MJ. Haploviz: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265
23. Poccelli S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. Plink: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–575
24. Hansen TK, Gall MA, Tarnow L, Thiel S, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A. Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 2006;166:2007–2013
25. Berger SP, Roos A, Mallat MJ, Schaapberder AF, Doxiadis I, van Kooten C, Dekker FW, Daha MR, de Fijter JW. Low pretransplantation mannan-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2007;18:2410–2422

1714 DIABETES, VOL. 57, JULY 2009